Replies to post #2712 on Generex Biotechnology Corp. (fka GNBTQ)

[TraderUsa]

Remember that the survival of AE37 is much better than Dendreon (DNDN) and Galena (GALE). We are talking about 46% of patients with breast cancer.

Market Opportunity minimum $4 billion.

IMO.

[G Bert]

There's new talk that Pfizer may split into two companies down the road. That may complicate the "if or when" aspect of buying all or part of Generex in the near term.


http://www.pharmpro.com/news/2012/03/pharmaceutical-companies-Pfizer-Moves-Higher-Amid-Persistent-Breakup-Talk/?et_cid=2561781&et_rid=245390750&linkid=http%3a%2f%2fwww.pharmpro.com%2fnews%2f2012%2f03%2fpharmaceutical-companies-Pfizer-Moves-Higher-Amid-Persistent-Breakup-Talk%2f